Key Takeaways:
Shares in Immunotech-B (06978.HK) collapsed nearly 27% after Chinese regulators rejected a conditional marketing application for its core drug candidate, EAL, dealing a major setback to its commercialization timeline.
The Center for Drug Evaluation (CDE) stated that while existing data showed a beneficial trend, it was insufficient for approval. "Confirmatory clinical trials are required in this population... a comprehensive evaluation of the product's benefit-risk profile cannot be conducted, and the marketing authorization application cannot be supported," the CDE notice said.
The rejection vaporized a significant portion of the company's market value, with the stock falling 26.688% before trading was halted. Immunotech said it has applied to resume trading on Wednesday and will proceed with the required confirmatory studies to support a re-submission under the regular approval process.
The decision delays a potential revenue stream from the company's flagship product, an Expanded Activated Lymphocyte (EAL) therapy. This type of immunotherapy relies on harvesting and activating a patient's own immune cells to fight disease. The need for further expensive and lengthy clinical trials will likely increase cash burn and puts significant pressure on the company to secure funding to bring EAL to market.
This article is for informational purposes only and does not constitute investment advice.
